EGFR and cancer: A number of EGFR inhibitors such as Lapatinib, Gefitinib, Afatinib and Erlotinib have been developed for use in cancer therapy [7] (Figure 1) as EGFR is overexpressed or constitutively active due to mutataions in various cancers.